Electra Therapeutics, Inc. (NASDAQ:ETRA – Get Free Report) Director Carl Gordon acquired 20,000 shares of the business’s stock in a transaction dated Monday, November 9th. The shares were acquired at an average cost of $8.24 per share, with a total value of $164,800.00. Following the acquisition, the director directly owned 5,234,578 shares of the company’s stock, valued at $43,132,922.72. This represents a 0.38% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Electra Therapeutics Stock Down 2.8%
ETRA traded down $0.23 on Tuesday, reaching $7.99. The company had a trading volume of 298,185 shares, compared to its average volume of 376,388. Electra Therapeutics, Inc. has a 52-week low of $6.86 and a 52-week high of $15.50.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on the company. HC Wainwright started coverage on Electra Therapeutics in a research note on Monday, October 26th. They set a “buy” rating and a $30.00 price target for the company. Evercore initiated coverage on Electra Therapeutics in a research report on Tuesday, October 13th. They issued an “outperform” rating and a $36.00 target price for the company. Zacks Research raised Electra Therapeutics to a “hold” rating in a research note on Wednesday, October 14th. Cantor Fitzgerald started coverage on shares of Electra Therapeutics in a research report on Tuesday, October 13th. They set an “overweight” rating on the stock. Finally, TD Cowen began coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They set a “buy” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $33.50.
About Electra Therapeutics
Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.
Read More
- Five stocks we like better than Electra Therapeutics
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Electra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
